Merck & Co., Inc.
Merck is a global pharmaceutical leader with a massive footprint in oncology, primarily through its blockbuster immunotherapy Keytruda (pembrolizumab). The company is a key player in the next generation of cancer vaccines, driven by its strategic co-development partnership with Moderna. This collaboration centers on the personalized mRNA-based cancer vaccine, mRNA-4157 (V940). The combination of V940 with Keytruda has shown highly promising results in clinical trials, notably reducing the risk of recurrence or death in high-risk melanoma patients. The combination is now progressing through a pivotal Phase 3 trial, positioning Merck at the forefront of combining checkpoint inhibition with personalized mRNA vaccine technology. The focus is on leveraging the patient’s own unique tumor signature (neoantigens) to create a tailored vaccine that primes the immune system’s T-cells to identify and destroy cancer cells. This commitment to precision medicine and cutting-edge vaccine platforms solidifies Merck’s leadership role in advancing therapeutic and prophylactic options in the rapidly evolving cancer vaccines market.
Latest Market Research Report on Cancer Vaccines Download PDF Brochure Now
GSK plc
GSK is a multinational pharmaceutical and biotechnology company with a strong history in vaccine development and a major focus on innovative immuno-oncology solutions. The company is recognized as a leading player in the cancer vaccines market. Its commitment extends from prophylactic (preventive) vaccines, such as Cervarix which protects against HPV-related cervical cancers, to the development of therapeutic cancer vaccines. GSK’s strategy is centered on harnessing the power of the human immune system and human genetics to accelerate the development of tumor-targeting therapies. By investing heavily in R&D and applying advanced research to understand the fundamental biology of cancer and immunology, GSK is working to create next-generation vaccine platforms. These efforts are aimed at addressing significant unmet needs across various cancer types, hastening the delivery of both preventive and therapeutic options to patients globally and reinforcing its reputation for pioneering science in the oncology vaccine landscape.
Moderna
Moderna is a pioneer in messenger RNA (mRNA) technology, which has become a foundational platform for next-generation cancer vaccines. The company is one of the major driving forces in the therapeutic cancer vaccine space, most notably through its partnership with Merck to co-develop the personalized mRNA vaccine, mRNA-4157 (V940). This vaccine is designed to be personalized, encoding up to 34 neoantigens derived from a patient’s unique cancer cell mutations. When administered, the mRNA instructs the patient’s own cells to produce these specific cancer-related proteins, thereby training the T-cells of the immune system to recognize and attack the cancerous cells. Positive Phase 2b results for V940 in combination with Keytruda in melanoma patients led to a Phase 3 trial initiation and Breakthrough Therapy Designation from the FDA. Moderna’s success demonstrates the profound potential of mRNA technology to create highly precise, scalable, and rapidly manufacturable personalized immunotherapies, marking a significant step toward making tailor-made cancer treatment a clinical reality.
BioNTech
BioNTech is a German biotechnology company globally recognized for its foundational work in mRNA technology and its rapid application in therapeutics, particularly in oncology. The company is a key player in the cancer vaccine field, leveraging its proprietary mRNA platform to develop both personalized and off-the-shelf vaccine candidates. Its pipeline includes BNT111, an investigational off-the-shelf mRNA cancer immunotherapy targeting four non-mutated melanoma-associated antigens. Furthermore, BioNTech is advancing personalized candidates like autogene cevumeran, which encodes up to 20 patient-specific neoantigens. Autogene cevumeran is currently in Phase 2 trials for difficult-to-treat cancers such as pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer, often administered alongside an immune checkpoint inhibitor. The company’s strategy focuses on generating a robust, neoantigen-specific T-cell response to prevent cancer recurrence, particularly in high-risk patients. BioNTech’s deep expertise in translating sophisticated mRNA science into clinical-stage oncology programs confirms its position as a major innovator in therapeutic cancer vaccine development.
Candel Therapeutics
Candel Therapeutics is a clinical-stage biotech based in the U.S. focused on developing novel viral immunotherapies, which fall under the therapeutic cancer vaccine umbrella. The company utilizes engineered viral platforms to generate robust, adaptive, and innate immune responses against cancer. Its lead candidate, CAN-2409, is a genetically modified adenovirus that delivers an antigen to the patient’s tumor, effectively turning the tumor site into an “off-the-shelf” vaccine factory. This candidate is currently in a Phase 3 trial for prostate cancer, showing encouraging results across various solid tumors. Candel’s pipeline also includes CAN-3110, a modified Herpes Simplex Virus (HSV) engineered to selectively destroy cancer cells while leaving healthy tissue intact. This oncolytic virus approach is being evaluated for early-stage brain cancers, targeting a protein highly expressed in brain tumor cells. By employing these sophisticated viral vectors, Candel aims to overcome the limitations of traditional cancer treatments and drive a systemic anti-cancer immune response.
Elicio Therapeutics
Elicio Therapeutics is a U.S.-based biotechnology company specializing in novel immunotherapies, with a core focus on developing therapeutic cancer vaccines. The company is pioneering an approach that targets the body’s lymph nodes, the natural “control centers” for the immune response, to enhance the effectiveness of their vaccines. Elicio’s proprietary Amphiphile (AMP) technology is the foundation for its lead candidate, ELI-002, which is an off-the-shelf therapeutic vaccine for patients with resected pancreatic cancer. The AMP technology allows vaccine components (antigens and adjuvants) to be precisely delivered to the lymph nodes, leading to a significantly stronger and more durable T-cell immune response against KRAS-mutated tumors. This targeted delivery mechanism is intended to circumvent the issues of systemic dilution and poor immunogenicity often associated with conventional vaccine administration. By concentrating the immune-stimulating components where the immune cells are most active, Elicio seeks to provide a highly potent and accessible treatment option for notoriously difficult-to-treat cancers like pancreatic cancer.
OSE Immunotherapeutics
OSE Immunotherapeutics is a French-based biotech that is actively involved in the development of innovative immunotherapies and therapeutic cancer vaccines. The company’s core strategy revolves around activating or regulating the immune system to fight cancer and inflammatory diseases. Its most advanced cancer vaccine candidate is Tedopi, which is an ‘off-the-shelf’ neoepitope vaccine designed to stimulate T-cells specifically in patients with non-small cell lung cancer (NSCLC) who have a secondary resistance to immune checkpoint inhibitors. The vaccine is composed of ten optimized T-cell epitopes from five tumor-associated antigens, selected for their high immunogenicity and potential to be recognized by a broad patient population. Tedopi has demonstrated encouraging clinical efficacy and a favorable safety profile in late-stage trials for this specific patient population. By focusing on patients who have exhausted standard immunotherapy options, OSE Immunotherapeutics is aiming to address a significant unmet medical need by leveraging its expertise in both adaptive and innate immunity to create powerful and targeted cancer treatments.
Imugene
Imugene is an Australian clinical-stage biotech company specializing in immuno-oncology, with a pipeline that includes therapeutic cancer vaccines and oncolytic virus therapies. The company is focused on developing treatments that harness the body’s own immune system to fight cancer. A key candidate is Vaxinia (CF33-hNIS), an oncolytic virus, which is a type of cancer vaccine that uses a modified virus to specifically infect and destroy cancer cells while also triggering an immune response against the tumor. Vaxinia is being evaluated in various solid tumor types. Additionally, Imugene is developing B-cell immunotherapies, which work by inducing the patient’s body to generate its own antibodies against cancer-related targets, offering an alternative approach to traditional monoclonal antibody therapies. Through its diverse portfolio of novel immuno-oncology assets, Imugene is committed to advancing next-generation treatments that are intended to be potent, scalable, and effective against a broad range of difficult-to-treat cancers, cementing its role in the global cancer vaccine landscape.
Immunomic Therapeutics
Immunomic Therapeutics is a U.S.-based clinical-stage biotechnology company that utilizes its proprietary UNiversal Intracellular Targeted Expression (UNITETM) platform to develop a wide range of therapeutic vaccines, including those for cancer and infectious diseases. The UNITETM platform works by directing tumor antigens to the lysosome, which is a key cellular compartment for processing antigens and generating a strong, long-lasting T-cell immune response. This proprietary technology is the foundation for their lead cancer vaccine candidate, ITI-1000, which is being developed to treat glioblastoma multiforme (GBM), one of the most aggressive forms of brain cancer. By focusing on creating robust, antigen-specific immune responses, Immunomic aims to improve upon the efficacy of current immunotherapies. The company’s technology is designed to overcome tolerance mechanisms and drive a highly effective and sustained anti-tumor immunity. Through its innovative UNITETM platform, Immunomic Therapeutics is positioned to generate differentiated and powerful therapeutic vaccines against a variety of cancers.
Scancell
Scancell is a clinical-stage biopharmaceutical company based in the U.K. that specializes in the discovery and development of novel immunotherapies, with a major focus on innovative therapeutic cancer vaccines. The company’s technology is based on its Moditope and ImmunoBody platforms. The ImmunoBody platform is used to develop DNA vaccines, like the lead candidate SCIB1/iSCIB1+, which is being developed for the treatment of melanoma. This vaccine is designed to stimulate high-avidity T-cells, which are crucial for recognizing and killing cancer cells effectively. The Moditope platform focuses on stimulating a powerful T-cell response against post-translationally modified (PTM) epitopes that are associated with a wide range of solid tumors. By targeting these specific PTM epitopes, which are less prone to mutation, Scancell aims to create treatments that are effective across a larger patient population and are resistant to cancer’s typical escape mechanisms. Scancell’s dual-platform approach underscores its commitment to generating potent and durable anti-tumor immunity.
Latest Market Research Report on Cancer Vaccines Download PDF Brochure Now